Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2024 04:00 ET | Source: Spherix Global Insights

Spherix Global Insights Expands Therapeutic Area Coverage into Hematology

EXTON, PA, June 10, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry,...
August 25, 2022 08:33 ET | Source: Allied Market Research

Global Hemoglobinopathies Market is Expected to Reach $7.0 Billion by 2031: Says AMR

Portland, OR, Aug. 25, 2022 (GLOBE NEWSWIRE) -- The Global Hemoglobinopathies Market size was estimated at $4.2 billion in 2021 and is expected to hit $7.0 billion by 2031, registering a CAGR of...
June 04, 2021 07:00 ET | Source: Imara, Inc.

Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress

Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial Imara to host conference call and live webcast on June 11, 2021 at...
May 11, 2021 07:00 ET | Source: Imara, Inc.

Imara Reports First Quarter 2021 Financial Results and Business Highlights

On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the...
May 04, 2021 07:00 ET | Source: Imara, Inc.

Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights

BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
May 04, 2020 07:00 ET | Source: Imara, Inc.

Imara Announces Appointment of Stephen M. Migausky as General Counsel

BOSTON, May 04, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
March 11, 2020 21:57 ET | Source: Imara, Inc.

IMARA Announces Pricing of Initial Public Offering

BOSTON, March 11, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to...